Site map
Pages
- About Us
- Biotech
- Blog
- Contact form submit
- Contact us
- Cookie policy
- CRO Services
- Events and conferences
- Front demo
- Gubra Green
- Gubra Resource Library
- GubraView: Transforming Data into Actionable Insights
- Home
- Investors Relations
- Latest news
- Newsletter signup
- Privacy policy
- Privacy policy event signup
- Terms of use
- Ventures
- Whisleblower
Blog
- Preclinical Women’s Health research from ovarian function to cardiorenal disease
- Advanced skeletal muscle histology in preclinical drug development
- 2026 industry trends in anti-obesity drug development
- Preclinical ovary histology: AI-assisted analysis of reproductive tissue and endpoints
- Supporting next-generation Alzheimer's disease research with quantitative whole-brain imaging
- Understanding the blood-brain barrier: Function, structure, and role in CNS drug delivery
- AI-based lung histology in preclinical IPF models: Bridging preclinical and clinical insight
- AI-based scoring and quantitative image analysis in preclinical kidney disease models
- Quantifying neurodegenerative disease with 3D Imaging: A new standard in preclinical CNS research
- What is in vivo pharmacology?
- Liver histology in preclinical models: AI-powered analysis for translational research
- FDA approves semaglutide (Wegovy®) for MASH: What does this mean for drug development and preclinical innovation?
- Which IPF model offers the highest translational relevance in preclinical research?
- How to choose the right model for atherosclerosis studies
- The role of preclinical fibrosis models in advancing kidney disease research
- What does c-Fos really measure? Interpreting neuronal activation in research
- Closing the preclinical gap: How better research models can transform women’s health
- AI at Gubra: Enhancing research, innovation, and decision-making
- AI in drug discovery: Key trends shaping therapeutics in 2025
- How GubraView™ transforms data accessibility in preclinical research
- Best Preclinical Models for CKD, DKD, and Kidney Fibrosis
- How to utilize whole brain imaging in preclinical obesity studies
- What is a preclinical CRO?
- 5 Reasons to choose Gubra as a preclinical partner
- Understanding c-Fos and its applications in CNS research
- Breakthroughs in innovative peptide therapeutics
- Important checklist for selecting the right preclinical CRO: 32 questions to ask
- Anti-obesity drug development: Industry trends in 2024
- FDA approved Madrigal’s Resmetirom (Rezdiffra<sup><small>®</small></sup>) as first drug treatment for MASH. What now?
- GAN DIO-MASH model is top-ranked by the LITMUS consortium
For further information